Three new trials will evaluate Xarelto for DVT, PE

  • April 10, 2014

Janssen Research & Development announced the launch of three new clinical trials to evaluate rivaroxaban for the treatment of deep vein thrombosis and pulmonary embolism.

The new studies are part of the EXPLORER global CV research program for rivaroxaban (Xarelto), which is funded by Janssen and Bayer HealthCare. The program will include more than 11,000 patients in 30 countries, according to a press release.

Full Story »
  • Filter By:
  • FDA approvals
  • FDA approves Pradaxa to treat DVT, PE

  • April 7, 2014
  • Boehringer Ingelheim announced that the FDA has approved dabigatran to treat deep vein thrombosis and pulmonary embolism.
    According to a company press...More »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!